We will begin reporting progress against our new commitments in our 2013 Corporate Responsibility Report.

Our forward-looking commitments around our behaviour are:

• Continue to drive a values-based approach to sales and marketing practices across the world, with the interests of consumers and patients at its core.
• Continue to ensure the interests and safety of patients and consumers are of paramount importance in the way we design and undertake our clinical trials, our product quality assurance and our monitoring and reporting of adverse events in ongoing product usage.
• Rigorously challenge the need for animal studies and work to minimise the impact on animal welfare, by investing in the development of alternative studies and sharing animal-based data.
• Address the UN Guiding Principles on Human Rights and Business across our own operations and our supplier relationships.
• Be as transparent as possible with our clinical trial data, including publishing clinical study reports (without patient-level data) for all outcome trials of medicines conducted by GSK and, within an appropriate process, making available to researchers access to anonymised patient-level data to further scientific enquiry.
• Demonstrate that all GSK interactions with patient advocacy groups and political stakeholders are conducted appropriately, ethically and transparently.